Regulatory Guidance on Protocol Amendments and Deviations
Protocol amendments and deviations are inevitable in the lifecycle of a pharmaceutical stability study. Whether driven by unforeseen events, regulatory feedback, or internal improvements, handling these changes in a compliant and transparent manner is critical. Regulatory authorities such as USFDA, EMA, WHO, and CDSCO scrutinize these activities during inspections, and improper management can lead to…
Read More “Regulatory Guidance on Protocol Amendments and Deviations” »